These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

861 related articles for article (PubMed ID: 21389095)

  • 21. Selective inactivation of CCR5 and decreased infectivity of R5 HIV-1 strains mediated by opioid-induced heterologous desensitization.
    Szabo I; Wetzel MA; Zhang N; Steele AD; Kaminsky DE; Chen C; Liu-Chen LY; Bednar F; Henderson EE; Howard OM; Oppenheim JJ; Rogers TJ
    J Leukoc Biol; 2003 Dec; 74(6):1074-82. PubMed ID: 12972507
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthetic full-length and truncated RANTES inhibit HIV-1 infection of primary macrophages.
    Ylisastigui L; Vizzavona J; Drakopoulou E; Paindavoine P; Calvo CF; Parmentier M; Gluckman JC; Vita C; Benjouad A
    AIDS; 1998 Jun; 12(9):977-84. PubMed ID: 9662193
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rescue of HIV-1 long-time archived X4 strains to escape maraviroc.
    Baatz F; Struck D; Lemaire M; De Landtsheer S; Servais JY; Arendt V; Schmit JC; Perez Bercoff D
    Antiviral Res; 2011 Dec; 92(3):488-92. PubMed ID: 22020304
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro effects of the CCR5 inhibitor maraviroc on human T cell function.
    Arberas H; Guardo AC; Bargalló ME; Maleno MJ; Calvo M; Blanco JL; García F; Gatell JM; Plana M
    J Antimicrob Chemother; 2013 Mar; 68(3):577-86. PubMed ID: 23152485
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Progesterone-induced inhibition of chemokine receptor expression on peripheral blood mononuclear cells correlates with reduced HIV-1 infectability in vitro.
    Vassiliadou N; Tucker L; Anderson DJ
    J Immunol; 1999 Jun; 162(12):7510-8. PubMed ID: 10358206
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).
    Marozsan AJ; Kuhmann SE; Morgan T; Herrera C; Rivera-Troche E; Xu S; Baroudy BM; Strizki J; Moore JP
    Virology; 2005 Jul; 338(1):182-99. PubMed ID: 15935415
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Extracellular high mobility group box-1 inhibits R5 and X4 HIV-1 strains replication in mononuclear phagocytes without induction of chemokines and cytokines.
    Cassetta L; Fortunato O; Adduce L; Rizzi C; Hering J; Rovere-Querini P; Bianchi ME; Alfano M; Poli G
    AIDS; 2009 Mar; 23(5):567-77. PubMed ID: 19194273
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HIV co-receptors as targets for antiviral therapy.
    Schols D
    Curr Top Med Chem; 2004; 4(9):883-93. PubMed ID: 15134547
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The relative activity of "function sparing" HIV-1 entry inhibitors on viral entry and CCR5 internalization: is allosteric functional selectivity a valuable therapeutic property?
    Muniz-Medina VM; Jones S; Maglich JM; Galardi C; Hollingsworth RE; Kazmierski WM; Ferris RG; Edelstein MP; Chiswell KE; Kenakin TP
    Mol Pharmacol; 2009 Mar; 75(3):490-501. PubMed ID: 19064629
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular anatomy of CCR5 engagement by physiologic and viral chemokines and HIV-1 envelope glycoproteins: differences in primary structural requirements for RANTES, MIP-1 alpha, and vMIP-II Binding.
    Navenot JM; Wang ZX; Trent JO; Murray JL; Hu QX; DeLeeuw L; Moore PS; Chang Y; Peiper SC
    J Mol Biol; 2001 Nov; 313(5):1181-93. PubMed ID: 11700073
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of beta-chemokines on human immunodeficiency virus type 1 replication, binding, uncoating, and CCR5 receptor expression in human monocyte-derived macrophages.
    Jiang Y; Jolly PE
    J Hum Virol; 1999; 2(3):123-32. PubMed ID: 10413363
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir.
    Westby M; Lewis M; Whitcomb J; Youle M; Pozniak AL; James IT; Jenkins TM; Perros M; van der Ryst E
    J Virol; 2006 May; 80(10):4909-20. PubMed ID: 16641282
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of dual/mixed tropic HIV-1 isolates by CCR5-inhibitors in primary lymphocytes and macrophages.
    Surdo M; Balestra E; Saccomandi P; Di Santo F; Montano M; Di Carlo D; Sarmati L; Aquaro S; Andreoni M; Svicher V; Perno CF; Ceccherini-Silberstein F
    PLoS One; 2013; 8(7):e68076. PubMed ID: 23874501
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic subtype-independent inhibition of human immunodeficiency virus type 1 replication by CC and CXC chemokines.
    Trkola A; Paxton WA; Monard SP; Hoxie JA; Siani MA; Thompson DA; Wu L; Mackay CR; Horuk R; Moore JP
    J Virol; 1998 Jan; 72(1):396-404. PubMed ID: 9420238
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CCR5 antagonists in the treatment of treatment-naive patients infected with CCR5 tropic HIV-1.
    Bredeek UF; Harbour MJ
    Eur J Med Res; 2007 Oct; 12(9):427-34. PubMed ID: 17933724
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New insights into the mechanisms whereby low molecular weight CCR5 ligands inhibit HIV-1 infection.
    Garcia-Perez J; Rueda P; Staropoli I; Kellenberger E; Alcami J; Arenzana-Seisdedos F; Lagane B
    J Biol Chem; 2011 Feb; 286(7):4978-90. PubMed ID: 21118814
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of CC chemokine receptor 5 (CCR5) inhibitors on the dynamics of CCR5 and CC-chemokine-CCR5 interactions.
    Nakata H; Kruhlak M; Kamata W; Ogata-Aoki H; Li J; Maeda K; Ghosh AK; Mitsuya H
    Antivir Ther; 2010; 15(3):321-31. PubMed ID: 20516552
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Blockade of CC chemokine receptor 5 (CCR5)-tropic human immunodeficiency virus-1 replication in human lymphoid tissue by CC chemokines.
    Margolis LB; Glushakova S; Grivel JC; Murphy PM
    J Clin Invest; 1998 May; 101(9):1876-80. PubMed ID: 9576751
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HIV blocked by chemokine antagonist.
    Arenzana-Seisdedos F; Virelizier JL; Rousset D; Clark-Lewis I; Loetscher P; Moser B; Baggiolini M
    Nature; 1996 Oct; 383(6599):400. PubMed ID: 8837769
    [No Abstract]   [Full Text] [Related]  

  • 40. Structure of CC Chemokine Receptor 5 with a Potent Chemokine Antagonist Reveals Mechanisms of Chemokine Recognition and Molecular Mimicry by HIV.
    Zheng Y; Han GW; Abagyan R; Wu B; Stevens RC; Cherezov V; Kufareva I; Handel TM
    Immunity; 2017 Jun; 46(6):1005-1017.e5. PubMed ID: 28636951
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.